CLLS
Cellectis S.A.
NASDAQ · Healthcare · Biotechnology · FR
$3.24
−2.41%Year over year
Reported trailing growth
- Revenue
- +0.5%
- EBITDA
- -83.4%
- EBIT
- -36.8%
- EPS
- -12.4%
- Free cash flow
- -20.4%
- Operating cash flow
- -25.6%
Forward estimates
Based on analyst estimates
- Revenue
- +73.1%
- EBITDA
- -46.4%
- EPS
- -62.9%
Three-year CAGR
- Revenue
- +56.1%
- EBITDA
- —
- EBIT
- +44.5%
- Net income
- -83.9%
- EPS
- -65.9%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026